Publicis lands Razorfish

Share this article:
Publicis will acquire Razorfish, a Microsoft-owned digital and interactive shop, for roughly $530 million, according to joint company statements (pdf here).

Razorfish will continue to operate under its brand name, and retain its management structure, led by CEO Bob Lord. David Deal, a Razorfish spokesperson, said the agency is anticipating “business as usual for Razorfish, including our health practice, and we do not foresee sweeping changes otherwise.”

Publicis will integrate Razorfish into its newly created VivaKi group, which incorporates digital and media assets such as Digitas and Denuo into a “nerve center,” tasked with global talent development and the creation of “a new approach to strategic scale across platforms, partners and technology,” according to the VivaKi website.

The acquisition follows a partnership between Publicis and Microsoft that was announced in June, allowing several of Publicis's agencies within the VivaKi group – which also includes Starcom MediaVest Group and ZenithOptimedia – to use Microsoft's Admira technology for media planning, buying and measurement. Admira is slated to launch during the fourth quarter of this year.

Razorfish's clients include Wyeth, Schering-Plough, Johnson & Johnson and others. The agency has hinted at formalizing its healthcare operations in recent months, but has been unable to comment on that development.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...